S Brassen1, G Adler. 1. Day Clinic for the Elderly and Clinical Neurophysiology Service, Central Institute of Mental Health, Mannheim, Germany.
Abstract
INTRODUCTION:Acetylcholinesterase inhibitor treatment enhances cholinergic neurotransmission and may thus partially reverse EEG slowing and memory impairment in Alzheimer patients within short time. METHODS: We studied the short-term effects of treatment with either rivastigmine or donepezil on EEG and memory performance in a group of 35 Alzheimer patients in an open, controlled design. RESULTS: Under a 1- or 2-week acetylcholinesterase inhibitor treatment, a decrease of global theta power and an improvement in the ADAS memory score were observed. However, compared to the control condition, only the theta power decrease remained significant and can be definitely considered a medication effect. DISCUSSION: EEG spectral analysis could be shown to rapidly reflect the cerebral cholinergic action of short-term acetylcholinesterase inhibitor treatment. Whether this action is related to the therapeutic efficacy of this type of drug must be determined in further longitudinal studies.
RCT Entities:
INTRODUCTION:Acetylcholinesterase inhibitor treatment enhances cholinergic neurotransmission and may thus partially reverse EEG slowing and memory impairment in Alzheimerpatients within short time. METHODS: We studied the short-term effects of treatment with either rivastigmine or donepezil on EEG and memory performance in a group of 35 Alzheimerpatients in an open, controlled design. RESULTS: Under a 1- or 2-week acetylcholinesterase inhibitor treatment, a decrease of global theta power and an improvement in the ADAS memory score were observed. However, compared to the control condition, only the theta power decrease remained significant and can be definitely considered a medication effect. DISCUSSION: EEG spectral analysis could be shown to rapidly reflect the cerebral cholinergic action of short-term acetylcholinesterase inhibitor treatment. Whether this action is related to the therapeutic efficacy of this type of drug must be determined in further longitudinal studies.
Authors: G Dunbar; P H Boeijinga; A Demazières; C Cisterni; R Kuchibhatla; K Wesnes; R Luthringer Journal: Psychopharmacology (Berl) Date: 2007-01-16 Impact factor: 4.530
Authors: Lucas S Broster; Juan Li; Benjamin Wagner; Charles D Smith; Gregory A Jicha; Frederick A Schmitt; Nancy Munro; Ryan H Haney; Yang Jiang Journal: J Clin Exp Neuropsychol Date: 2018-02-20 Impact factor: 2.475
Authors: Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Claudio Babiloni; Xianghong Arakaki; Hamed Azami; Karim Bennys; Katarzyna Blinowska; Laura Bonanni; Ana Bujan; Maria C Carrillo; Andrzej Cichocki; Jaisalmer de Frutos-Lucas; Claudio Del Percio; Bruno Dubois; Rebecca Edelmayer; Gary Egan; Stephane Epelbaum; Javier Escudero; Alan Evans; Francesca Farina; Keith Fargo; Alberto Fernández; Raffaele Ferri; Giovanni Frisoni; Harald Hampel; Michael G Harrington; Vesna Jelic; Jaeseung Jeong; Yang Jiang; Maciej Kaminski; Voyko Kavcic; Kerry Kilborn; Sanjeev Kumar; Alice Lam; Lew Lim; Roberta Lizio; David Lopez; Susanna Lopez; Brendan Lucey; Fernando Maestú; William J McGeown; Ian McKeith; Davide Vito Moretti; Flavio Nobili; Giuseppe Noce; John Olichney; Marco Onofrj; Ricardo Osorio; Mario Parra-Rodriguez; Tarek Rajji; Petra Ritter; Andrea Soricelli; Fabrizio Stocchi; Ioannis Tarnanas; John Paul Taylor; Stefan Teipel; Federico Tucci; Mitchell Valdes-Sosa; Pedro Valdes-Sosa; Marco Weiergräber; Gorsev Yener; Bahar Guntekin Journal: Alzheimers Dement Date: 2021-04-15 Impact factor: 16.655